---
document_datetime: 2023-09-21 18:26:16
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/replagal-epar-procedural-steps-taken-authorisation_en.pdf
document_name: replagal-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5126465
conversion_datetime: 2025-12-27 13:23:41.448396
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company TKT Europe AB submitted on 4 July 2000 an application for Marketing Authorisation to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Replagal,  in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr. Hans van Bronswijk Co-Rapporteur: Dr. Per Nilsson

## Scientific Advice:

The  applicant  received  Scientific  Advice  from  CPMP  on  24  May  1999.  The  Scientific  Advice pertained to parts II, III and IV of the dossier.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 18 July 2000.
- The Rapporteur's first assessment report was circulated to all CPMP  Members on 27 September 2000. The Co-Rapporteur's first assessment report was circulated to all  CPMP Members on 26 September 2000.
- During  the  meeting  on  14-16  November  2000  the  CPMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  applicant.  The  final  consolidated  list  of  questions  was  sent  to  the applicant on 16 November 2000.
- The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on  24 November 2000.
- The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  sites  between  28 November 2000 and 1 December 2000 and on 17 January 2001 was issued on 29 January 2001.
- The Rapporteur circulated the response assessment report on the company's responses to the list of questions to all CPMP Members on 4 January 2001 Part III and IV, 10 January 2001 Part I and II.
- During the meeting on 23-25 January 2001, the CPMP agreed on a list of outstanding issues to be addressed by the applicant in writing and if necessary during an oral explanation. The list of outstanding  issues  was  sent  to  the  applicant  on  25  January  2001.  A  final  revised  list  of outstanding issues was sent to the applicant on 2 February 2001.
- The applicant provided written information on these outstanding issues to all CPMP members on  5  February  2001.  The  joint  Rapporteur/Co-rapporteur  assessment  report  on  the  written responses to the list of outstanding issues was circulated to all CPMP members on 12 February 2001.
- During the CPMP meeting on 28 February 2001, outstanding quality and clinical issues were addressed by the applicant during an oral explanation before the CPMP.

<div style=\"page-break-after: always\"></div>

- During the meeting on 27 - 29 March 2001 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Replagal on 29 March 2001.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 3 August 2001.